FDA Drug Topics: Cannabis Products and the Potential Impact on Patients - October 29, 2024
FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present our FDA Drug Topic series of educational webinars targeting the needs of all health care professionals, including physicians, physician assistants, nurse practitioners, nurses, pharmacists, pharmacy technicians, and certified public health professionals. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!
On Tuesday, October 29, 2024, CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: FDA Drug Topics: Cannabis Products and the Potential Impact on Patients. This webinar provided insights into the landscape of the cannabis marketplace and some general information on how products are manufactured and regulated. It discussed clinical and pharmacological considerations along with known drug-drug interactions that can impact patients. The presentation identified common misconceptions on the use and safety of cannabis products and provided attendees with accurate information to help prevent the spread of misinformation. We provided attendees with a greater knowledge of ways to identify and report adverse events associated with these products to FDA, as well as suggestions on how to create a safe space to discuss patient use of these products.
Cannabis Products and the Potential Impact on Patients (PDF - 4.2 MB)
Key Webinar Points (PDF - 662 KB)
Activity Outline and Continuing Education Information: U.S. Food & Drug Administration (fda.gov)